Publications dans lesquelles il/elle collabore avec T. Castillo Triviño (18)

2024

  1. Bacteria–Fungi Interactions in Multiple Sclerosis

    Microorganisms, Vol. 12, Núm. 5

2023

  1. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

    Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193

2022

  1. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

    Multiple Sclerosis and Related Disorders, Vol. 63

2021

  1. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (I)

    Revista de neurologia, Vol. 72, Núm. 11, pp. 397-406

  2. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (II)

    Revista de neurologia, Vol. 72, Núm. 12, pp. 433-442

2020

  1. The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis

    Cells, Vol. 9, Núm. 1

2016

  1. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2R1441G Parkinson's disease

    Movement Disorders, Vol. 31, Núm. 3, pp. 335-343

  2. SncRNA (microRNA &snoRNA) opposite expression pattern found in multiple sclerosis relapse and remission is sex dependent

    Scientific Reports, Vol. 6

2015

  1. Age gene expression and coexpression progressive signatures in peripheral blood leukocytes

    Experimental Gerontology, Vol. 72, pp. 50-56

  2. Identification of ncRNAs as potential therapeutic targets in multiple sclerosis through differential ncRNA - mRNA network analysis

    BMC Genomics, Vol. 16, Núm. 1

  3. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry

2014

  1. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients

    Multiple Sclerosis Journal, Vol. 20, Núm. 14, pp. 1851-1859

  2. Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis

    Biomarkers in Medicine, Vol. 8, Núm. 5, pp. 653-661

  3. Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progression

    PLoS ONE, Vol. 9, Núm. 2

2013

  1. Clinical response to thalidomide in the treatment of intracranial tuberculomas: Case report

    Clinical Neuropharmacology, Vol. 36, Núm. 2, pp. 70-72

2012

  1. HLA-DRB1*15:01 and multiple sclerosis: A female association?

    Multiple Sclerosis Journal, Vol. 18, Núm. 5, pp. 569-577

  2. Hepatitis autoinmune en un paciente con esclerosis múltiple en tratamiento con acetato de glatiramero.

    Revista de neurologia

2009

  1. Differential micro RNA expression in PBMC from multiple sclerosis patients

    PLoS ONE, Vol. 4, Núm. 7